According to reports from Business Standard, Amerise Biosciences reported a standalone net loss of ₹0.08 crore in the quarter ended June 2026, representing an increase from the net loss of ₹0.01 crore recorded during the corresponding quarter of the previous financial year. The company's financial performance for the quarter showed no sales revenue reported during both the current and previous quarter periods.
As reported by Business Standard, the company's financial results for the quarter ended June 2026 showed a net loss increase of ₹0.07 crore compared to the same quarter in the previous financial year. The absence of sales revenue in both quarters indicates that Amerise Biosciences has not generated any income during the reporting periods, contributing to the consistent net losses.
According to the financial data reported by Business Standard, the company's quarterly net loss of ₹0.08 crore in Q1 FY27 represents a 70% increase from the ₹0.01 crore loss recorded in the corresponding quarter of the previous financial year. The consistent pattern of losses without any revenue generation indicates ongoing operational challenges for the biosciences company.
